FIREFLY: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With BRAF-Altered, Recurrent or Progressive Low-Grade Glioma

Viewing: SA

Filter by

Trial Stage
  • Trial Stage
  • Closed to Recruitment
  • In Development
  • Open
  • Preparing to Open
Location
  • Location
  • New Zealand
  • NSW
  • QLD
  • SA
  • TAS
  • VIC
  • WA
Disease Type
  • Disease Type
  • Bone Cancers (Ewing Sarcoma/Osteosarcoma)
  • Brain and other Central Nervous System (CNS) Tumours
  • Germ Cell Tumours
  • Hodgkin Lymphoma
  • Kidney (Renal) Tumours
  • Leukaemia
  • Liver tumours
  • Neuroblastoma
  • Non-Hodgkin Lymphoma
  • Other
  • Soft Tissue Sarcomas
Disease Stage
  • Disease Stage
  • Newly diagnosed
  • Other
  • Relapsed/Recurrent

FIREFLY: A Phase 2, Open-Label, Multicenter...

Brain and other Central Nervous System (CNS) Tumours
Status: Open | NSW, QLD, SA, VIC, WA

Relapsed/Recurrent
Read more

LOXO-TRK-15003: A Phase 1/2 Study of...

Bone Cancers (Ewing Sarcoma/Osteosarcoma), Brain and other Central Nervous System (CNS) Tumours, Germ Cell Tumours, Kidney (Renal) Tumours, Liver tumours, Neuroblastoma, Soft Tissue Sarcomas
Status: Closed to Recruitment, Open | NSW, SA, VIC

Newly diagnosed, Relapsed/Recurrent
Read more

Interfant-21

Leukaemia
Status: Open | NSW, QLD, SA, VIC, WA

International collaborative treatment protocol for infants under one year with KMT2A rearranged acute lymphoblastic leukemia or mixed phenotype acute leukemia

Newly diagnosed
Read more

Deflexifol® at Relapse Trial (DART)

Brain and other Central Nervous System (CNS) Tumours
Status: Open | NSW, QLD, SA, VIC, WA

Phase I/II Trial of Deflexifol for Refractory or Recurrent Paediatric Central Nervous System (CNS) Tumours

Newly diagnosed, Relapsed/Recurrent
Read more

BIOMEDE

Status: Closed to Recruitment | New Zealand, NSW, QLD, SA, VIC, WA

Biological Medicine for Diffuse Intrinsic Pontine Glioma Eradication

Newly diagnosed
Read more

rEECur

Bone Cancers (Ewing Sarcoma/Osteosarcoma), Soft Tissue Sarcomas
Status: Open | New Zealand, NSW, QLD, SA, VIC, WA

An international randomised controlled trial of chemotherapy for the treatment of recurrent and primary refractory Ewing sarcoma

Relapsed/Recurrent
Read more

LGG-Avastin

Brain and other Central Nervous System (CNS) Tumours
Status: Open | New Zealand, NSW, QLD, SA, VIC, WA

A phase II, open-labeled, multi-center, randomized controlled trial of Vinblastine +/- Bevacizumab (Avastin) for the treatment of chemotherapy-naïve children with unresectable or progressive low grade glioma

Newly diagnosed, Relapsed/Recurrent
Read more

PARC

Bone Cancers (Ewing Sarcoma/Osteosarcoma), Brain and other Central Nervous System (CNS) Tumours, Leukaemia, Neuroblastoma
Status: Closed to Recruitment | NSW, QLD, SA, VIC, WA

An international phase I/II study evaluating the safety and activity of Pegylated recombinant human Arginase (BCT-100) in Relapsed/refractory cancers of Children and young adults.

Relapsed/Recurrent
Read more

PRISM

Bone Cancers (Ewing Sarcoma/Osteosarcoma), Brain and other Central Nervous System (CNS) Tumours, Germ Cell Tumours, Hodgkin Lymphoma, Kidney (Renal) Tumours, Leukaemia, Liver tumours, Neuroblastoma, Non-Hodgkin Lymphoma, Soft Tissue Sarcomas
Status: Closed to Recruitment | NSW, QLD, SA, TAS, VIC, WA

PRecISion Medicine for Children with Cancer

Newly diagnosed, Relapsed/Recurrent
Read more

All posts loaded.

All posts loaded.

Join our newsletter

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

Email info@anzchog.org   |  

Level 6, TRF Building, Hudson Institute, 27-31 Wright St, Clayton VIC 3168

ANZCHOG acknowledges Traditional Owners of Country throughout Australia and recognises the continuing connection to lands, waters and communities. We pay our respect to Aboriginal and Torres Strait Islander cultures, and to Elders both past and present. We acknowledge Māori as tangata whenua of Aotearoa New Zealand and as Treaty partners with the Crown as agreed in Te Tiriti o Waitangi. 

We are committed to creating a safe and welcoming environment that embraces all backgrounds, cultures, sexualities, genders and abilities.